Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue

Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.